Hydro completes Phase III prostate cancer enrollment

Hydro Med (Cranbury, N.J.) completed enrollment in a Phase III trial of its Histrelin long-acting LHRH hydrogel implant to treat prostate cancer. In January, Shire (LSE:SHP; SHPGY) gave back certain r...